Search Results - "SMITH, C. H"

Fructose and lactose intolerance and malabsorption testing: the relationship with symptoms in functional gastrointestinal disorders by Wilder‐Smith, C. H., Materna, A., Wermelinger, C., Schuler, J.

“…Summary Background The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders…”
Get full text

Atopic dermatitis: the skin barrier and beyond by Tsakok, T., Woolf, R., Smith, C.H., Weidinger, S., Flohr, C.

“…Summary Background Atopic dermatitis is the most common chronic inflammatory skin disorder, affecting up to 20% of children and 10% of adults in industrialized…”
Get full text

Predictors of response to a low‐FODMAP diet in patients with functional gastrointestinal disorders and lactose or fructose intolerance by Wilder‐Smith, C. H., Olesen, S. S., Materna, A., Drewes, A. M.

“…Summary Background Diets low in fermentable sugars (low‐FODMAP diets) are increasingly adopted by patients with functional gastrointestinal disorders (FGID),…”
Get full text

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) by Bruin‐Weller, M., Thaçi, D., Smith, C.H., Reich, K., Cork, M.J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., Hultsch, T., Chen, Z., Pirozzi, G., Graham, N.M.H., Shumel, B.

“…Summary Background Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent…”
Get full text

Response to: ‘Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)’: reply from the authors by Cro, S., Smith, C.H

“…We believe that there is significant interest in the role of IL‐1 in the pathomechanism of palmoplantar pustulosis. However, the APRICOT study failed to…”
Get full text

Combat‐training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers by Li, X., Kan, E. M., Lu, J., Cao, Y., Wong, R. K., Keshavarzian, A., Wilder‐Smith, C. H.

“…Summary Background Gastrointestinal (GI) symptoms are common in soldiers in combat or high‐pressure operational situations and often lead to compromised…”
Get full text

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) by Yiu, Z.Z.N., Mason, K.J., Hampton, P.J., Reynolds, N.J., Smith, C.H., Lunt, M., Griffiths, C.E.M., Warren, R.B.

“…Summary Background Real‐world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with…”
Get full text

Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses by Samarasekera, E.J., Sawyer, L., Wonderling, D., Tucker, R., Smith, C.H.

“…Summary The majority of people with psoriasis have localized disease, where topical therapy forms the cornerstone of treatment. We set out to summarize…”
Get full text

Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls by Wilder-Smith, C H, Schindler, D, Lovblad, K, Redmond, S M, Nirkko, A

“…Background and aims: Many patients with irritable bowel syndrome (IBS) show intestinal hypersensitivity to distension and sensitisation after repeated…”
Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update by Smith, C.H., Yiu, Z.Z.N., Bale, T., Burden, A.D., Coates, L.C., Edwards, W., MacMahon, E., Mahil, S.K., McGuire, A., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Uthman, O.A., Woolf, R.T., Manounah, L., Ezejimofor, M.C., Exton, L.S., Mohd Mustapa, M.F.

“…Linked Comment: Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online…”
Get full text

Risk of cancer in patients with psoriasis on biological therapies: a systematic review by Peleva, E., Exton, L.S., Kelley, K., Kleyn, C.E., Mason, K.J., Smith, C.H.

“…Summary Background Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively…”
Get full text

Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic by Mahil, S.K., McSweeney, S.M., Kloczko, E., McGowan, B., Barker, J.N., Smith, C.H.

“…Summary Clinical question Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis (PsA) in obese individuals? Background Obesity…”
Get full text

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) by Mahil, S.K., Wilson, N., Dand, N., Reynolds, N.J., Griffiths, C.E.M., Emsley, R., Marsden, A., Evans, I., Warren, R.B., Stocken, D., Barker, J.N., Burden, A.D., Smith, C.H.

“…Summary Background The ‘treat to target’ paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis…”
Get full text

Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies by Maybury, C.M., Jabbar-Lopez, Z.K., Wong, T., Dhillon, A.P., Barker, J.N., Smith, C.H.

“…Summary Methotrexate (MTX) is an effective treatment for psoriasis but concerns regarding the development of liver fibrosis prevent optimal use. The primary…”
Get full text

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 by Smith, C.H., Jabbar‐Lopez, Z.K., Yiu, Z.Z., Bale, T., Burden, A.D., Coates, L.C., Cruickshank, M., Hadoke, T., MacMahon, E., Murphy, R., Nelson‐Piercy, C., Owen, C.M., Parslew, R., Peleva, E., Pottinger, E., Samarasekera, E.J., Stoddart, J., Strudwicke, C., Venning, V. A., Warren, R.B., Exton, L.S., Mohd Mustapa, M.F.

“…Plain language summary available online…”
Get full text

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series by Willsmore, Z.N., Woolf, R.T., Hughes, C., Menon, B., Kirkham, B., Smith, C.H., Pink, A.E.

Get full text

Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated by Sears, A.V., Woolf, R.T., Gribaleva, E., Abdelrahman, W., Robbie, S., Menon, B., Kirkham, B., Smith, C.H., Pink, A.E.

Get full text

A Validation Study of Multicenter Diffusion Tensor Imaging: Reliability of Fractional Anisotropy and Diffusivity Values by FOX, R. J, SAKAIE, K, FISHER, E, LEE, J.-C, DEBBINS, J. P, LIU, Y, ARNOLD, D. L, MELHEM, E. R, SMITH, C. H, PHILIPS, M. D, LOWE, M

“…DTI is increasingly being used as a measure to study tissue damage in several neurologic diseases. Our aim was to investigate the comparability of DTI measures…”
Get full text

Screening for anxiety and depression in people with psoriasis: a cross‐sectional study in a tertiary referral setting by Lamb, R.C., Matcham, F., Turner, M.A., Rayner, L., Simpson, A., Hotopf, M., Barker, J.N.W.N., Jackson, K., Smith, C.H.

“…Summary Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well‐being in people with…”
Get full text

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis by Mahil, S.K., Ezejimofor, M.C., Exton, L.S., Manounah, L., Burden, A.D., Coates, L.C., Brito, M., McGuire, A., Murphy, R., Owen, C.M., Parslew, R., Woolf, R.T., Yiu, Z.Z.N., Uthman, O.A., Mohd Mustapa, M.F., Smith, C.H.

“…Summary Background The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform…”
Get full text